NEW YORK (GenomeWeb News) – Rosetta Genomics said yesterday that it has completed its previously announced direct offering of approximately $5.1 million in securities.

Rosetta has received net proceeds of approximately $4.5 million after deducting placement agent fees and other offering expenses.

The molecular diagnostics developer said that it plans to use the $4.5 million in proceeds from the offering for general corporate purposes and to support the development of its microRNA-based diagnostic pipeline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.